Get the Stockscreener App
5.40
3.40%
-0.19
After Hours:
5.40
Insight Molecular Diagnostics Inc stock is traded at $5.40, with a volume of 82,257.
It is down -3.40% in the last 24 hours and down -16.15% over the past month.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
See More
Previous Close:
$5.59
Open:
$5.41
24h Volume:
82,257
Relative Volume:
0.22
Market Cap:
$174.37M
Revenue:
$4.06M
Net Income/Loss:
$-50.22M
P/E Ratio:
-3.3364
EPS:
-1.6185
Net Cash Flow:
$-25.37M
1W Performance:
-0.74%
1M Performance:
-16.15%
6M Performance:
-15.23%
1Y Performance:
+0.00%
1-Day Range:
$5.27
$5.72
1-Week Range:
$4.95
$5.72
52-Week Range:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Name
Insight Molecular Diagnostics Inc
Sector
Industry
Phone
949-409-7600
Address
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
5.40 | 180.50M | 4.06M | -50.22M | -25.37M | -1.6185 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 187.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 136.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.78B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.27B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.91 | 37.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Initiated | Lake Street | Buy |
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
Insight Molecular Diagnostics Inc Stock (IMDX) Latest News
Insight Molecular Diagnostics Inc. Actuals & Estimates (BOATS:IMDX) - TradingView
IMDX Forecast — Price Target — Prediction for 2027 - TradingView
Insight Molecular Diagnostics and ASTS Award Grant for Health Economics Study of In-House vs. Send-Out dd-cfDNA Testing in Kidney Transplantation - Quiver Quantitative
iMDx and ASTS fund $100,000 study on kidney transplant testing costs - Stock Titan
Insight Molecular Diagnostics Ord Shs (IMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insight Molecular Diagnostics Ord Shs (IMDX) Institutional Confidence - TradingKey
IMDX SEC FilingsInsight Molecular Diagnostics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insight Molecular Diagnostics Validates GraftAssure Assay Superiority - HarianBasis.co
Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment - Insider Monkey
12 High-Growth Micro-Cap Stocks to Buy Now - Insider Monkey
Insight Molecular Diagnostics Ord Shs (IMDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Insight Molecular Diagnostics (NASDAQ: IMDX) shareholders back plan share increase - Stock Titan
Insight Molecular Diagnostics Inc. Announces Favorable Head-To-Head Data On Imdx's Graftassure With Competing NGS Assay Published In Clinical Chemistry - marketscreener.com
New lab test rivals DNA sequencing to monitor kidney transplants - Stock Titan
Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry - Sahm
[Form 4] Insight Molecular Diagnostics Inc. Insider Trading Activity - Stock Titan
Director Arno Andrew of Insight Molecular (IMDX) receives 32,331-share stock grant - Stock Titan
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) Stock Price, News & Analysis - Kalkine
IMDX Q1 2026 Earnings: Narrowing Losses with 55% EPS Surprise Amid Revenue DisclosuresBuyback Announcement Report - newsline.com
Insight Molecular Diagnostics Inc. Announces Publication of GraftAssure CM-Score Demonstrating Superior Performance in Transplant Rejection Monitoring - Quiver Quantitative
IMDX GraftAssure Assay Sets New Standard in Screening - GlobeNewswire
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation - Yahoo Finance Australia
Study: New kidney transplant model doubles reliability of positive results - Stock Titan
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress - The Manila Times
IMDX Q1 2026 Earnings: EPS Beat Lifts Sentiment Despite No RevenueForward EPS Estimate - newsline.com
Insight Molecular Diagnostics Inc Highlights Graftassure Technology and Announces Grant Winners At American Transplant Congress - marketscreener.com
iMDx to Showcase GraftAssure Technology at American Transplant Congress and Announce Research Grant Winners - Quiver Quantitative
In-house transplant rejection test heads to key Boston conference - Stock Titan
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
IMDX Q1 2026 Earnings: Strong EPS Beat Driven by Cost Discipline and Operational EfficiencyEarnings Decline Risk - newsline.com
Insight Molecular Diagnostics (IMDX) Posts Modest Gain; Resistance Test LoomsFactor Crowding - newsline.com
IMDX Q1 2026 Earnings: EPS beats estimates by 55% despite revenue absenceFiscal Year Earnings - newsline.com
Insight Molecular Diagnostics (IMDX) Rallies 5.75% as Bullish Momentum Builds Near Key ResistanceSynthetic Short - newsline.com
Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings: EPS Surprises to the Upside During Pre‑Revenue Phase - The Legal Advocate
Earnings call transcript: Insight Molecular Diagnostics’ Q1 2026 performance and strategic outlook - Investing.com Australia
Insight Molecular Diagnostics Balances Progress and Cash Burn - TipRanks
Insight Molecular Diagnostics Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IMDX) 2026-05-17 - Seeking Alpha
Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission - Yahoo Finance
BTIG reiterates Neutral on Insight Molecular stock amid FDA review By Investing.com - Investing.com Nigeria
BTIG reiterates Neutral on Insight Molecular stock amid FDA review - Investing.com India
Insight Molecular Q1 2026 Earnings Call Transcript - Sahm
Insight Molecular Diagnostics Inc (IMDX) Q1 2026 Earnings Call H - GuruFocus
Needham Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Insight Molecular Diagnostics (IMDX) Sees Positive Engagement wi - GuruFocus
Insight Molecular Diagnostics expects about $0.25M Q2 2026 revenue while projecting second-quarter cash burn above $9M - MSN
Insight Molecular Diagnostics (IMDX) Q1 2026 Earnings: EPS not d - GuruFocus
Insight Molecular Diagn 1Q Rev $32,000 >IMDX - Moomoo
Insight Molecular Diagnostics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Insight Molecular Diagnostics Q1 2026 sees stock rise 2.41% - Investing.com Australia
Insight Molecular Diagnostics Inc Stock (IMDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.76%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):